ArticleParasites & vectors2025
Evaluation of VectoMax FG application frequency for the control of Aedes albopictus and Culex species in urban catch basins: evidence from a randomised controlled trial.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVectoMax FG (Valent BioSciences, Libertyville, IL, USA) is a biological mosquito larvicide, combining Bacillus thuringiensis var. israelensis and Lysinibacillus sphaericus. Bacillus thuringiensis var. israelensis demonstrates a low propensity for resistance development, whereas L. sphaericus exhibits prolonged residual effectiveness in organically polluted aquatic environments. The manufacturer recommends treatments at least every 4 weeks; however, recent evidence suggests that less frequent applications may achieve comparable effectiveness, which is important for reducing operational costs related to larvicide volume and labour as well as reduced environmental exposure.
methodsTo provide data-driven guidance for vector control programmes targeting Aedes albopictus in catch basins, we conducted a randomised controlled trial in Basel, Switzerland, from May to October 2024. A total of 180 catch basins, randomly selected from 768 basins in an urban area infested with Ae. albopictus, were assigned to treatment intervals of 2, 4, 6, 8 or 10 weeks, alongside untreated controls. Emergence traps were used to capture adult mosquitoes developing from larvae within the basins, allowing comparison of mosquito abundance reductions across treatment frequencies. Generalised additive and linear mixed effects models were applied to quantify the effects of larvicide application frequency, temperature, precipitation and time since treatment on mosquito and non-target dipteran populations.
resultsSuppression of all taxa peaked within 20-30 days post-treatment. Over 50% reductions in mosquito abundance were sustained for up to 10 weeks following treatment, with Culex spp. exhibiting persistent suppression exceeding 90% for up to 6 weeks, and Ae. albopictus maintaining comparably high levels of suppression for up to 4 weeks.
conclusionsWhile Culex spp. responded well even at longer intervals, Ae. albopictus required more frequent treatment to avoid rebound. Our findings show effective (> 90%) suppression in both Ae. albopictus and Culex spp. when VectoMax FG was reapplied at 4-week intervals. Increased application frequency not only enhanced overall effectiveness but also reduced variability in mosquito abundance, contributing to more stable vector control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.